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Abstract
Background: There is limited research and literature on the data management challenges encountered in multi-
arm, multi-stage platform and umbrella protocols. These trial designs allow both (1) seamless addition of new
research comparisons and (2) early stopping of accrual to individual comparisons that do not show sufficient
activity. FOCUS4 (colorectal cancer) and STAMPEDE (prostate cancer), run from the Medical Research Council Clinical
Trials Unit (CTU) at UCL, are two leading UK examples of clinical trials implementing adaptive platform protocol
designs. To date, STAMPEDE has added five new research comparisons, closed two research comparisons following
pre-planned interim analysis (lack of benefit), adapted the control arm following results from STAMPEDE and other
relevant trials, and completed recruitment to six research comparisons. FOCUS4 has closed one research
comparison following pre-planned interim analysis (lack of benefit) and added one new research comparison, with
a number of further comparisons in the pipeline. We share our experiences from the operational aspects of running
these adaptive trials, focusing on data management.
Methods: We held discussion groups with STAMPEDE and FOCUS4 CTU data management staff to identify data
management challenges specific to adaptive platform protocols. We collated data on a number of case report form
(CRF) changes, database amendments and database growth since each trial began.
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Discussion: We found similar adaptive protocol-specific challenges in both trials. Adding comparisons to and
removing them from open trials provides extra layers of complexity to CRF and database development. At the start of
an adaptive trial, CRFs and databases must be designed to be flexible and scalable in order to cope with the
continuous changes, ensuring future data requirements are considered where possible. When adding or stopping a
comparison, the challenge is to incorporate new data requirements while ensuring data collection within ongoing
comparisons is unaffected. Some changes may apply to all comparisons; others may be comparison-specific or
applicable only to patients recruited during a specific time period. We discuss the advantages and disadvantages of the
different approaches to CRF and database design we implemented in these trials, particularly in relation to use and
maintenance of generic versus comparison-specific CRFs and databases. The work required to add or remove a
comparison, including the development and testing of changes, updating of documentation, and training of sites,
must be undertaken alongside data management of ongoing comparisons. Adequate resource is required for these
competing data management tasks, especially in trials with long follow-up. A plan is needed for regular and pre-
analysis data cleaning for multiple comparisons that could recruit at different rates and periods of time. Data-cleaning
activities may need to be split and prioritised, especially if analyses for different comparisons overlap in time.
Conclusions: Adaptive trials offer an efficient model to run randomised controlled trials, but setting up and conducting
the data management activities in these trials can be operationally challenging. Trialists and funders must plan for
scalability in data collection and the resource required to cope with additional competing data management tasks.
Keywords: Adaptive trials, Platform protocol, Multi-arm multi-stage (MAMS), Trial conduct, Data management, Database,
Randomisation, Case report form, Methodology
Background
Master protocols for clinical trials, including adaptive pro-
tocols, are becoming more commonplace due to their effi-
ciency in achieving results faster [1, 2]. Traditionally,
protocols describe trials that compare one research arm
against a single control arm, and both arms remain open
throughout the life of the trial. The protocols we give as
examples incorporate multiple comparisons in the context
of a disease or treatment, where some may be added or
dropped over time [2–6]. There may or may not be a
shared control arm across comparisons. Some trial arms
may open later than others, and entirely new comparisons
can be introduced [7]. Trial arms may close to recruitment
when there are sufficient participants in a specific compari-
son or adaptive elements using pre-defined interim analyses
can be used to close recruitment early for a comparison
while allowing other trial arms to continue to recruit.
The potential for adaptive protocols to evaluate treat-
ments faster and more efficiently than traditional rando-
mised controlled trials has been demonstrated [8, 9] and
the statistical and trial management issues discussed [5, 10,
11]. However, there has been little discussion about the data
management challenges in making substantial changes to a
trial. We describe several challenges, using examples from
two relevant protocols centrally coordinated from the Med-
ical Research Council (MRC) Clinical Trials Unit (CTU) at
UCL, London, that have opened and closed several com-
parisons: STAMPEDE (Systemic Therapy in Advancing or
Metastatic Prostate Cancer: Evaluation of Drug Efficacy) [7,
11–14] in prostate cancer and FOCUS4 (Molecular selec-
tion of therapy in colorectal cancer: a molecularly stratified
randomised controlled trial programme) [4, 6, 15, 16] in
colorectal cancer. Our co-submitted companion paper fo-
cuses on the trial management aspects of these trials. We
identified several data management challenges either spe-
cific to adaptive platform protocols or exacerbated by the
use of these novel trial designs, and we discuss possible ap-
proaches to tackling these challenges.
Methods
Trial characteristics
Both STAMPEDE and FOCUS4 implemented multi-arm,
multi-stage, stratified (clinically stratified and/or
biomarker-stratified) and platform elements [7, 11, 16], in-
cluding adding and closing comparisons. Table 1 summarises
these trial characteristics. Figure 1a and b summarise the
comparisons opened and closed over time. Additional trial
schemas can be found in Additional file 1: Figures S6–S10.
Discussion groups
Data management challenges were identified by
semi-structured discussion groups chaired by LM, ST
and DH and attended by CTU trial staff, including trial
managers/coordinators, data managers, statisticians, sys-
tem analysts and database programmers. We reviewed
each stage of the sponsor’s trial-specific data manage-
ment process [17], from case report form (CRF) devel-
opment to database lock, and highlighted those
challenges specific to or amplified by their adaptive de-
sign. We identified and discussed known or potential so-
lutions to address or mitigate the challenges, discussing
with the trial teams how successful each solution has
Hague et al. Trials          (2019) 20:294 Page 2 of 16
been or might be, including potential advantages and
disadvantages of each approach. We categorised data
management processes based on well-established proce-
dures in our unit and other organisations [18], highlight-
ing those completed by the CTU on behalf of the
sponsor. We also collated data on CRF and database
changes since the beginning of each trial using CRF ver-
sion histories, database version histories, database saved
data points and change control tickets raised.
Findings
Our preparations and group discussions identified five
broad areas capturing key data management processes
which are impacted specifically by adaptive platform de-
signs. These are described in Table 2. Table 3 shows total
number per year of the following: comparisons opened and
closed, CRF releases, generic and comparison-specific
CRFs, database designs, database response tables, database
releases and change control tickets raised. This is refer-
enced in the CRF and database discussion below.
CRF development and maintenance
There can be CRF updates during the lifetime of a trad-
itional trial, such as clarification of protocol wording,
changing the trial design based on emerging data from
other trials, or correcting errors on the CRFs. These tend
to arise from previously unplanned, isolated events. Devel-
opment of CRFs for adaptive trials and platform protocols
need to take into account data collection requirements
from all comparisons open to recruitment while allowing
for any other comparisons already in follow-up and with
flexibility for future comparisons to be added. Platform
protocols may require repeated, substantial changes when
new comparisons are added or follow-up is completed for
old comparisons. CRFs must be clearly version-controlled.
In adaptive trials and platform protocols, there are likely
to be several versions. It is essential that sites can easily
identify the current version.
Table 3 (column D) shows that both trials have added
or amended CRFs each year they have been open to re-
cruitment. These changes not only coincided with com-
parison changes (Table 3, columns B and C) but also
Table 1 Characteristics of STAMPEDE and FOCUS4
Trial characteristic STAMPEDE FOCUS4
Disease setting Prostate cancer Colorectal cancer
Registration numbers
ISRCTN ISRCTN78818544 ISRCTN90061546
EudraCT 2004-000193-31 2012-005111-12
ClinicalTrials.gov NCT00268476 Not available
Date first patient randomised October 2005 January 2014
Multiple comparisons Yes Yes
Multi-stage elements Yes Yes
Comparisons for specific sub-groups (stratified elements) Yes (defined by metastases; diabetic status)
Pending (defined by biomarker)
Yes (defined by biomarker)
Shared control arm Yes No
Initial comparisons open 5 2
New research comparisons added 5 3
Research comparisons closed for lack of benefit 2 1
Research comparisons reached recruitment target 6 Pending
Eligibility criteria revised Yes Yes
Stratification criteria revised Yes Yes
New biomarker classifications added Pending Yes
Updates of standard of care 3 0
Patients recruited so far > 10,000 > 900
Data collected on paper CRFs Yes Limiteda
Data entered from source notes straight into database No Yes
Data entry Staff at CTU Staff at sites (excepta)
Randomisation Sites call CTU to randomise Sites call CTU to randomise
Abbreviations: CRFs Case report forms, CTU Clinical trials unit, FOCUS4 Molecular selection of therapy in colorectal cancer: a molecularly stratified randomised
controlled trial programme, STAMPEDE Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
aRegistration, biomarker collection and serious adverse events
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included other protocol amendments and minor updates.
Both trials also had a spike of releases in the first few years
the trial was open. These were changes after review and
feedback from initial releases and protocol clarifications
rather than major content updates.
New comparisons may have particular data require-
ments not already recorded, such as adverse event (AE)
categories or treatment collection. External collaborators
may have varying expectations about what data are re-
quired. Capturing this information can also risk
A
B
Fig. 1 a STAMPEDE comparison history. b FOCUS4 comparison history
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complicating CRFs, making them harder to use, possibly
having an impact on data quality. Table 3 (column D)
shows the number of releases per year, but it does not
show the additional resource and attention required to
retain present, incorporate future and/or remove past
data requirements, which was a challenge highlighted by
staff who worked on CRF updates.
Amending generic CRFs with specific questions for new
comparisons can make question numbering unwieldy. A
possible solution is grouping similar questions on the
CRF, with each section group lettered and the numbers
restarting. Adding new questions to the end of relevant
sections is then easier (see Additional file 1: Figure S11 for
an example). It may be worth considering whether ques-
tion numbers on the screen are necessary at all.
Using the same visit schedule across comparisons with
assessments harmonised across all patients will simplify
data collection requirements. Unbalanced assessments be-
tween arms can cause bias in assessment of outcome mea-
sures, particularly if there is a shared control arm. New
comparison-specific visit schedules may be unavoidable,
and these assessments could be harder to incorporate into
existing CRFs. One way to collect the data is to use
generic CRFs across comparisons where possible, sup-
plemented by comparison-specific sections. STAM-
PEDE primarily uses generic CRFs, collecting the same
data for all patients with some comparison-specific
data collected using conditional questions highlighted
by guidance text and supplemented with some
treatment-specific CRFs. FOCUS4 uses fewer generic
CRFs, using comparison-specific CRFs instead of con-
ditional questions. Therefore, the FOCUS4 total num-
ber of CRFs has increased at a greater rate than
STAMPEDE where total number has not greatly risen.
Table 3 contains the total number of CRFs, including
breakdown by generic and comparison-specific CRFs
for each trial (columns E, F and G). Table 4 summa-
rises the advantages and challenges of generic and
comparison-specific CRFs in this setting.
Practical examples from STAMPEDE CRF amendments
In STAMPEDE, baseline assessment and outcome data are
the same across all of the comparisons and are the most
Table 3 CRF and database statistics per year
1Excluding ‘stratified STAMPEDE’ pilot 2018 (different database and CRFs not discussed here)
2Any new or updated version. FOCUS4 includes all database designs
3A new database design was introduced in 2017 for FOCUS4 Comparison C, but the data are currently saved to the same responses table
4Tickets include requests for updates to database, reports, website, randomisation server. The unit did not mandate using ticket system pre-2012, so these data
are not representative of all changes
Table 2 Data management processes affected by adaptive
platform design
1. CRF development and maintenance
2. Databases
a. Design, including incorporating new CRF, question and validation
requirements
b.Table structure
c. Support
e. Electronica data capture
f. Randomisation system
3. Training and documentation
4. Competing, concurrent tasks: data queries and CRF chases
5. Competing, concurrent tasks: opening new comparisons while
managing existing comparisons
CRF Case report form
aAlso known as ‘remote’ data capture
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likely visits to have generic CRF sections. Treatment details,
toxicity assessments and some eligibility criteria are
comparison-specific, and data for these areas are captured
on comparison-specific CRFs or comparison-specific sec-
tions of generic CRFs, as seen in Fig. 2.
The original requirements for collecting AEs in
STAMPEDE differ from those of some added compari-
sons. Originally, patients were required to report AEs on
a generic follow-up form only until their first disease
progression event. After this first event, an abridged ver-
sion of the CRF could be used for the patient, the
post-progression follow-up CRF, where AEs no longer
needed to be recorded. A new comparison required AEs
to be reported while patients were receiving treatment
and treatment continued beyond a first progression
event. This meant that the CRF name ‘post-progression’
follow-up CRF was no longer accurate, so CRFs were
re-developed accordingly. In this instance, we separated
the follow-up and AE questions into two CRFs, with
guidance on the follow-up CRF explaining when the AE
CRF should be completed. This is an example of how we
had to make significant changes to a generic CRF as new
requirements arose that could not be anticipated.
The data collection for shared control arm patients may
also change over time due to requirements for new
comparisons. One of STAMPEDE’s added comparisons
requires specific metabolic and cardiovascular events not
previously collected. Comparative data must be collected
for the contemporaneous control arm for this comparison.
A new comparison-specific section was added to the
follow-up CRF, which applies to both the experimental
arm (arm K) and the contemporaneous control arm (arm
A) patients, but not to control arm patients randomised
before this date. Figure 2 shows the conditional CRF guid-
ance required. There are usually multiple new require-
ments for new comparisons.
Databases: design, including incorporating new CRF,
question and validation requirements
The database for a clinical trial is developed within a clin-
ical data management system (CDMS), producing a vali-
dated software tool for CRF data entry and data
management, providing data for analysis [17]. Each trial’s
database design (also known as study definition) within the
chosen CDMS is programmed individually to reflect the
CRF requirements as initially specified from the protocol.
In adaptive protocols, as comparisons are added or
closed, the database design must also adapt, and therefore
it is important to plan for flexibility and scalability when
first developed so future requirements are deliverable.
Table 4 Advantages and challenges of generic and comparison-specific case report forms
CRF type Generic Comparison-specific
Advantages • Efficient if data requirements are similar across
comparisons
• Data are captured consistently across comparisons
• Capacity to still make sections specific by arm,
comparison, sites, patient sub-group, etc.
• CRF changes need to be made on only one set of CRFs,
reducing time taken for development/amendments
• Generally fewer CRFs overall
• Efficient if data requirements are substantially
different across comparisons
• Only data required for a single comparison is
captured
• Not likely to become as complex as generic CRFs.
May therefore be easier for site staff to use.
• Each CRF is easier to maintain for comparison-
specific changes
• Not all changes across life of the trial must be
included, only those during the lifespan of the CRF
Challenges • Adding comparisons/questions.
- Increasing length and complexity as additional data
requirements are added
- Question numbering can become unwieldy if new
questions are needed within the existing CRF
- Unanticipated changes may require existing CRF to be
redeveloped or a new CRF to be developeda
- Shared control arm participants may be affected by new
comparisons requiring conditional questions/sections to
be addedb
• Less flexibility in collecting data
- Must ensure CRFs can be relevant for all comparisons
• Changes external to the trial may be more likely to
impact generic CRFsc
- Universal coding lists changing the names or values of
items on the listd
- Changes in standard of care
• Generic changes will need to be made across
specific CRFs separately, increasing maintenance
time and risk of errors.
• More CRFs in total
- Can take longer to train site staff on each
individual CRF if they are different from each
other
- Version control/CRF tracking. Multiple similar
versions with differing version numbers. Data
management staff must be more careful to ensure
correct version is used.
• If a shared control arm is being used, CRFs for this
arm must still capture data required for multiple
comparisons whilst ensuring this does not
introduce bias; additional questions may lead to
events being more likely to be reported or
introduce other biases. Some questions may need
to be added to all comparison-specific CRFs to
avoid this.
CRF Case report form
aSee practical examples from STAMPEDE CRF amendments
bEasier to accomplish in electronic data capture with conditional formatting in the study database
cCould still be a challenge for comparison-specific CRFs
dE.g. Common Terminology Criteria for Adverse Events (CTCAE) update V3.0 to V4.0
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Flexibility and scalability challenges have been experi-
enced in adaptive-only trials previously [19], but the plat-
form protocol(s) introduces additional considerations. The
changes required for new or amended CRFs need to be in-
corporated while keeping existing data valid, increasing
the number of CRFs, fields, validations and/or conditional
processing required over time. This requires thorough
testing and subsequent maintenance of the database(s).
The database design must be carefully considered so
future changes can be efficiently incorporated. A single
generic database could be set up with the intention of
incorporating all future changes in one system, or, alter-
natively, multiple comparison-specific databases with
shared elements may be more appropriate.
STAMPEDE started in 2005 as a six-arm, five-stage,
multi-arm, multi-stage trial [12] and later was adapted
into a platform protocol in 2011 to incorporate multiple
further questions, starting them efficiently and avoiding
competing trials. Therefore, its single-database design
was not developed with future comparisons in mind.
Each addition increases the risk of issues with system
performance, redundancy and legacy issues. Testing dur-
ing change control can become more challenging; how-
ever, only one database requires testing and maintaining.
This approach is easier if individual sections of core
CRFs can remain generic, alongside any independently
updated, comparison-specific CRFs.
FOCUS4 was developed in 2013 specifically to incorporate
multiple, biomarker-stratified and non-stratified compari-
sons. A single-database design was envisioned to capture
future comparisons within the main trial period (i.e.,
post-randomisation). In addition to this, another database
design is used to capture data for all comparisons during the
registration period. During the addition of a new compari-
son (FOCUS4-B), we found the additional requirements in-
creased the complexity of conditional processing and testing
time to burdensome levels. For the most recently added
comparison (FOCUS4-C), the decision was made by the
trial team and in-house developers to use a separate data-
base design, copying shared elements where possible.
Requirements were simpler and elements of the existing
design were used, which reduced testing burden for each
database. However, multiple databases may require test-
ing, which increases the volume, if not the complexity, of
required documentation. Additional effort is also required
to ensure question text, category codes and variable
names remain consistent where applicable because generic
questions/CRFs may have to be duplicated if an identical
CRF cannot be easily copied across multiple databases.
Table 3 (column J) shows that the release of database
versions across both trials and all designs (for FOCUS4) is
a fairly common occurrence. Many of these changes will
relate to new comparisons, but other protocol changes,
change requests and fixes are also included in these num-
bers. There is also variation in major or minor changes
within a single release. Staff who worked on requirements,
programming and testing the database reported an in-
creased maintenance workload that comes with regular
major change control of the database design in both trials.
This matches the multiple number of releases each year,
including releases not related to when comparisons were
added or closed.
As with amending CRFs, the extra time needed to re-
tain present, incorporate future and/or disable past data
requirements is not reflected by only the number of re-
leases. This was again stated as a challenge by relevant
members of staff in the focus groups. Figure 3a (STAM-
PEDE) and b (FOCUS4) show the different approaches
used in each trial for incorporating comparisons in sin-
gle- or multiple-database designs.
Database: table structure
Inevitably, platform protocols will collect more informa-
tion than traditional two-arm trials over time. The target
maximum number of patients recruited to a platform
protocol design will further increase with each added
comparison, as will the total number of records saved in
the database, which could potentially negatively impact
system performance. The particular third-party CDMS
we used experienced performance issues, especially with
data views and extraction, with the increasing amount of
data entered into its single underlying table. This was
likely compounded by the complex single-database de-
sign used for multiple comparisons, as detailed in the
previous section. In 2013, the single-database table for
STAMPEDE had reached 12,178,762 saved data points
(including CRF data, hidden, derived, ‘not applicable’ and
missing questions). The memory was increased and
servers upgraded, but problems persisted in part due to
the older technology used by this CDMS, so the vendor
Fig. 2 Comparison-specific section of STAMPEDE’s generic follow-up case report form
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recommended a database split. The database was split
into five identically structured copies as per the design
shown in Fig. 1a, meaning data were held separately for
arbitrarily defined subsets of patients, requiring merging
these data in separate software before any processing or
analysis could be performed. Initially, the split was made
according to site (e.g., sites 1–11 in database 1). In 2016,
two additional databases were created for patients enter-
ing the new comparison. However, each database was spe-
cific to an arm, A (control) and K (metformin), rather than
further splits by site in order to keep growth limited to the
length of follow-up required for that arm. A further database
was created in 2017 for the next arm L (tE2). Figure 4a
shows the total number of data items per database (showing
A
B
Fig. 3 a Increasing complexity of shared, single-database design when adding and closing comparisons in STAMPEDE. b Shared and unique
database designs when adding and closing comparisons in FOCUS4. a and b key: 1Arm G (abiraterone comparison) incorporated in 2011. 2Arms
H–K sequentially incorporated over time; arms B–F closed. 3Current comparisons incorporated as per Fig. 1 (split into eight copies as seen in
Fig. 4a). 4Initial release in 2014 with two databases, registration period and main trial period. Comparisons N and D are within the same database
design. 5FOCUS4-B added within the existing database design and database. 6FOCUS4-C added within the same database with a new database
design. FOCUS4-D and -B closed to recruitment. FOCUS4-N continues recruitment
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the database splits). The next-largest trial at the unit using
this CDMS is the ICON8 (Weekly Chemotherapy in Ovar-
ian Cancer) study, with 9,037,766 data points. The trial has
completed recruitment, but follow-up continues. It does not
currently have the same performance problems.
Splitting databases requires ‘stitching’ the data into
one dataset for analyses and day-to-day administrative
oversight. We achieved this using external reporting
tools and statistical software. These challenges can cer-
tainly be alleviated using statistical software in the ana-
lysis environment, but this shifts the resource from the
operational members of the trial team, who use validated
reports, to only staff with statistical expertise. The staff
inputting data spent more time locating the right patient
in the right database, where an additional report was
built in order to search for the correct database. Staff
also need to switch between databases when work-
ing on different sites and/or comparisons, which re-
quires logging out and in again in the CDMS we
use. If the protocol includes research comparisons
that share contemporaneously recruited control pa-
tients, as in STAMPEDE, it may be useful to split
the database by arm rather than by comparison.
Splits by site, patient sub-group or date of randomisation
A
B
Fig. 4 a Data items in STAMPEDE databases over time. b Data items in FOCUS4 databases over time
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are other options, but they may not prevent the need for
further splits if additional comparisons increase target re-
cruitment. FOCUS4’s comparison-specific splits of
database designs are currently saved within a single
database. Additional databases may be needed in
the future if the chosen CDMS has large amounts
of data accumulating in the database table(s). Figure
4b shows the current growth of data in FOCUS4,
which also includes the separate registration
database.
It is therefore critical to be aware of how the database
tables are structured in the CDMS and to understand
how large amounts of subject data and associated meta-
data are stored and how this impacts the system per-
formance. Using a system where data are stored in only
one table could be used if relatively few comparisons
may be added. Partitioning where data are saved may be
more suitable for platform protocols that plan to repeat-
edly add new comparisons. In hindsight, STAMPEDE
should have partitioned data from the outset or selected
a CDMS with greater capacity for growth, but the plans
for multiple future comparisons were not known when
this decision was made, nor were the CDMS limitations
well documented.
Database: support
The chosen CDMS must be supported throughout the tri-
al’s life. Platform protocols tend to have longer lives than
traditional trials, so they must be supported for this time.
There will likely be an increased reliance on user and
developer expertise to maintain, assess impact of
changes on and update the database(s) due to the in-
crease in complexity of the databases in these trials over
time. STAMPEDE’s CDMS demonstrated poor perform-
ance with certain features, including data entry, after the
vendor released a significantly updated version of their
system. They had simultaneously dropped support for
the previous version, which had not had these problems.
Therefore, some ‘screens’ had to be redeveloped by the
trial team to address this issue. This issue also affected
the ongoing traditionally designed trials, but the longev-
ity of platform protocols means there is greater potential
for a protocol to have this problem.
Databases: electronic data capture
A key challenge in developing any electronic data capture
(eDC) system, where site staff enter data directly from
source notes, is ensuring it is particularly user-friendly for
a large number of mixed-experience site staff. Platform
protocols can quickly become complex, and development
must consider site staff who may have many other trials
competing for their attention.
Database design and development timelines for trials
are commonly challenging; the effect can be exacerbated
in platform protocols with competing timelines arising
from amendment activities (see more below). The time
to approval of a new comparison has potential to be
shorter than starting a new trial, giving less time for de-
velopment. Therefore, developing an eDC system that is
intuitive and with all eCRFs and associated features
ready on ‘comparison activation day’ requires careful
planning and resource allocation. An advantage of eDC
over paper data collection is the automatic opening and
closing of comparison-specific questions or eCRFs, as
seen in Fig. 2, which are widespread in this type of trial.
Databases: randomisation system
An added comparison will require changes to randomisa-
tion systems such as blocks or minimisation calculations,
questions, multi-randomisation sub-groups, stratification
factors and/or eligibility criteria. Some patients may be-
come ineligible for allocation to new treatments within a
multi-way randomisation. An example of this is patients
with diabetes, who needed to be excluded from the
randomisation to metformin comparison added to STAM-
PEDE. The randomisation tool, regardless of whether
it is within the CDMS system(s), must incorporate
these changes seamlessly without impacting ongoing
recruiting comparisons.
STAMPEDE was first implemented in the unit’s
in-house randomisation system in 2005. The trial uses
minimisation with a random element, balancing over
several stratification factors. With each new added com-
parison the allocation totals and stratification totals within
each allocation have been reset to zero, preventing imbal-
ances in future allocations. This is easier to handle with
minimisation than with blocks. Checks for existing imbal-
ances are done before the strata tables are reset in case
any adjustments need to be incorporated. For example,
the current randomisation for STAMPEDE has three eligi-
bility groups or ‘buckets’: (1) eligible for both metformin
and tE2 comparisons, (2) eligible for metformin compari-
son only and (3) eligible for tE2 comparisons only. Prior
to this (September 2016 to June 2017), there was only one
recruiting comparison, eligible for metformin only. The
system had to be able to reset the ‘eligible for metformin
only’ group, in addition to creating the new groups. Strati-
fication factors have also been removed, added and
amended over time with different protocol amendments.
For example, different arms are balanced by which add-
itional standard-of-care treatment the patient is receiving:
‘none’ or ‘docetaxel’. This has since been updated to strat-
ify by ‘none’, ‘docetaxel’ and ‘abiraterone’.
FOCUS4 uses the same in-house randomisation sys-
tem. Third-party suppliers were consulted but did not
have the capability to sufficiently change the system
once it was set up, so it could not be used. The
biomarker stratification in FOCUS4 is based on an
Hague et al. Trials          (2019) 20:294 Page 10 of 16
underlying hierarchy of prevalence for each biomarker,
with each patient offered randomisation within a par-
ticular biomarker-defined comparison based on genetic
analysis or allocation to a non-biomarker-stratified com-
parison. Ensuring the hierarchy is correct in both the
randomisation system and the CDMS is essential to the
correct randomisation of the trial participants. When
adding or removing a comparison, the trial statistician
will write a new version of the hierarchy, which will then
be developed in both systems and will be rigorously
tested. Lessons learnt for issues in CDMS and random-
isation may apply to other systems, such as drug supply
and trial management systems.
Training and documentation
Staff training, at sites and the trials unit, is an obvious re-
quirement for all trials. Platform protocols are likely to in-
crease the complexity of data management activities, so
further consideration may be necessary to plan how this
training will be provided effectively. Protocol longevity
means that initial site training is likely inadequate to cover
the protocol’s life, accounting for staff turnover.
Additional specific training is also needed as recruiting
arms change. Each added comparison can mean extensive
practical changes to the data collection requirements
(CRFs and systems), so additional training is needed for
both central and site staff. Data management documenta-
tion (e.g., data management plans) will also need reviewing
and updating with each change in recruiting arms.
STAMPEDE and FOCUS4 developed a ‘main’ set of
training slides/documents, including information applic-
able to all comparisons (e.g., safety reporting), supple-
mented by separate training slides/documents for
comparison-specific information. This balance meant
that trials unit and site staff could be adequately trained
across all comparisons. It was also fairly straightforward
to add information for new comparisons by adding a
new sub-section/sub-document, but if any general trial
information needed updating, then this needed to hap-
pen only once in the main document. We anticipate that
less site training would be required on data management
fundamentals for a single-platform protocol than for all
of the separate two-arm trials to address the same ques-
tions. However, the resource required for updating
training materials and internal data management docu-
mentation needs careful consideration, and the import-
ance of maintaining these materials should not be
forgotten.
Competing, concurrent tasks: data queries and CRF
chases
Multiple comparisons may require their own specific
analyses. The timing of multiple analyses could occur
close together, given possible variation in comparison
activation dates and recruitment rates. Individual com-
parisons are likely to require targeted data chases
pre-analysis, and it is important to do this without
neglecting regular cleaning of other comparisons. Chas-
ing and querying should be performed concurrently across
all comparisons where possible. If this becomes overwhelm-
ing for those sites with substantial numbers of patients,
splitting up of the queries/CRFs being chased may be re-
quired, such as splitting by patients across all arms or CRF
type. Comparison-specific data cleaning before analyses will
require reports or systems to be able to filter for relevant
data, such as by research arm, comparisons and date of
randomisation.
If a trial is using a control arm that is shared across
comparisons and comparison-specific analyses are per-
formed in preparation for analysis, then there may be
higher frequency of data chases over time in shared con-
trol arm patients compared with patients in each specific
research arm. This may mean that a higher relative pro-
portion of missing event-reporting forms is seen in a re-
search arm than in the control arm before the relevant
comparison-specific data chase is sent. To address this,
sufficient time must be allocated to chase any missing
event forms in the newer research arm. The statistician
may otherwise be more likely to find an imbalance in
event reporting between control and research arms
when they initially extract and review the data. This is a
potential risk to data integrity, and checks for any imbal-
ance in missing expected forms and triggered event
forms should be in place before completing any analysis,
as with any trial design. To our knowledge, no trials
have reported any such imbalance. The additional chases
for the shared control arm may also beneficially allow
more time for sites to focus on the research comparison
before an analysis if fewer control arm patients’ queries
require resolving, having been sent previously.
Competing concurrent tasks: opening new comparisons
while managing existing comparisons
The trial must be resourced for both ongoing data man-
agement and the work required for the addition of a new
comparison. There is likely to be an increase in concur-
rent data management tasks for a platform protocol
(Fig. 5). A traditional trial is only ever at one stage of its
life cycle. Tasks such as CRF and database development
and preparing site training documents are performed be-
fore trial opening and thus before there are data to be
managed. Trials unit data management staff can then
proceed to performing tasks specific to the recruitment
stages of a trial, such as data entry/data checking, resolv-
ing data queries and chasing missing CRFs. However, in a
platform protocol, particularly with adaptive elements, the
comparisons are at different stages. CRF and database up-
dates and site training for new arms might coincide with
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the intensive data-cleaning activities needed before ana-
lysis of each comparison, alongside the expected routine
data management tasks for an open trial in follow-up.
The opening and closing to recruitment of compari-
sons is often resource-intensive and may need accom-
plishing in a relatively short time, particularly following
an interim analysis. Failing to plan and acquire adequate
resource could result in rushing CRF planning or data-
base updates or in not allowing time for sufficient data
cleaning alongside these activities. This could jeopardize
the quality of existing and/or future data.
A platform protocol will almost certainly trigger many
changes to the database and related systems. For ex-
ample, the STAMPEDE team has raised a new ‘ticket’ for
necessary updates to the database design or development
of a report at least once every month since August 2014
(Table 3, column I). These updates were undertaken
alongside processing randomisations for 4200 patients
since that date and follow-up of all patients still on trial.
An example of an issue caused by this increase in concur-
rent data management tasks comes from STAMPEDE. An
arm needed to be added to the trial within a relatively short
amount of time due to delays in finalising some of the spe-
cific details of the data that needed to be collected for the
new arm. The trial CRFs then needed to be updated, and
these updates also needed to be added to the database and
thoroughly tested. However, the need to keep on top of
entering the large volume of data received daily for
the active trial arms was also pressing, ahead of a
key analysis for another comparison. A plan to bal-
ance the available data management resource across
these tasks was agreed, with the need to avoid a sig-
nificant data entry backlog being prioritised in the
short term. This meant the team could not complete
all database updates and testing before the new add-
itional comparison was activated, so some completed
CRFs arrived at the CTU before the database was
ready to accept them and thus could not yet be en-
tered. With the key analysis deadline achieved, all
available resources were then channelled into finalis-
ing the database changes so that these new CRFs
could then be entered. Regular discussion and
re-prioritisation were important throughout this
period to ensure the team continued to work across
these tasks effectively.
Discussion
Recommendations
We have reflected on our experiences with this plat-
form protocol and can make a series of recommenda-
tions to other researchers, with each linked to potential
risk to patient safety or data integrity. These are set out
in Table 5.
Fig. 5 Competing, concurrent tasks in traditional trial design versus adaptive platform protocol
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Table 5 Summary of recommendations
Process Risk to patient safety or data integrity? Recommendations
CRF development
and maintenance
Increased number and/or complexity of CRFs may lead
to erroneous completion, impacting data quality, possibly
relating to safety data.
Additional time required to incorporate new data
requirements may impact other data management tasks.
Consider which CRFs are going to be generic or
comparison-specific for initial and additional
comparisons.
Consider possible future impact of visit schedule
and data collection changes.
Randomisation
system
Ineligibility checks incorrectly implemented or unable
to be implemented at all, leading to patients incorrectly
being randomised to a specific comparison or at all.
Allocation and stratification weighting to new and
ongoing comparisons incorrectly implemented or
unable to be implemented at all.
Ensure choice of randomisation systema can
incorporate changes to
questions, eligibility, multi-randomisation
sub-groups, tables,
weightings and stratification factors.
Check for imbalances before resetting tables; adjust
if appropriate.
Thorough test scripts and testing of updates before
go-live.
Database: design Increasing complexity increases time to incorporate
new data requirement.
Complexity, legacy issues and redundancy may impact
database performance, taking time away from other tasks.
Complexity, legacy issues and redundancy may increase
risk of incorrect specification, programming and testing,
which risk incorrect data capture and validation in the live
environment.
Database change control or requirement for entirely
new database design may impact timelines to activate
a comparison or other data management tasks.
The chosen CDMSa must flexibly incorporate
multiple number of
increasingly conditional changes.
Consider single or multiple modular database
designs to
incorporate multiple comparisons. The former may
be efficient if
limited, non-complex changes are associated with
new comparisons The latter may increase the
number of databases to maintain but
protect complexity and limit lifespan. Try to find
logical separations
of the database designs if using multiple.
The chosen CDMSa should have a proven record in
functioning with large amounts of data in terms of
overall number of trial participants, questions and
validations.
Minimise long eCRFs and on-screen validation
number and complexity.
Thorough test scripts and testing of updates before
go-live.
Re-use shared elements to save development time.
Database: table
structure
The growing number of data points in a CDMS may impact
database performance, which risks existing data if any errors
in saving occur.
This may add time taken to enter data, taking resources
away from other trial tasks.
Ensure the chosen CDMS’sa capacity for data storage
is scalable for the forecasted patients and additional
comparisons.
Use multiple databases or set up CDMS to partition
data in multiple
tables. Consider logical separation of expected data
across multiple
comparisons.
Processes should be in place to manage data if
partitioned (e.g.,
reports, data mergers)
Database: support Existing trial data may be at risk if new bugs occur
in the database which can no longer be fixed. Additional
work may be required to transfer data to new CDMS or
CDMS version.
Updating an already complex database may require
existing in-depth knowledge. If staff change, then the
database may not be updated or regression tested
appropriately, risking data capture and validation.
Investigate whether predicted support for chosen
CDMSa lines up
with predicted timelines of maximum number of
comparisons to
be added when starting the trial.
Training and
documentation
Additionally complex guidance for multiple
comparisons risks lack of understanding and
misreporting of data at site or mishandling of
data at sponsor.
Prepare to regularly update an increasingly large set
of documentation and train sites on generic and
comparison-specific
data management processes.
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Limitations of review
We have explored some data management challenges we
experienced with two established, adaptive platform pro-
tocols. This is not exhaustive; we did not cover issues in
preparing datasets for archiving or onward data sharing.
Both protocols use the same CDMS; other CDMSs may
bring other challenges. Others may prefer alternative so-
lutions to all of these challenges, but our experiences
and lessons provide a good starting point for discussion.
Successes and future work
Despite the aforementioned challenges, we have success-
fully opened five new research comparisons in STAM-
PEDE, with scientific approval for a sixth and three new
research comparisons in FOCUS4. STAMPEDE has re-
ported the primary analyses for seven comparisons, with
another expected in 2019, as well as multiple interim
analyses seen only by the Independent Data Monitoring
Committee (IDMC). FOCUS4 has had one formal in-
terim analysis, in which the FOCUS4-D drug did not
meet the pre-specified activity level, and therefore the
study closed to recruitment early. In addition, reviews in
FOCUS4 were seen only by the IDMC.
The conduct efficiencies arising from the design are
reflected in some data management processes; for ex-
ample, updating CRFs for new comparisons is likely less
burdensome than starting afresh. There may be many
new requirements for a comparison, but the balance of
generic and specific CRFs should allow flexibility and re-
duces the effort required to update. Each additional
comparison provides the opportunity to improve CRF de-
sign and improve data-cleaning processes (including vali-
dations) in the database compared with a new trial where
problems may be harder to spot before CRFs and systems
have been used for data collection. This is a double-edged
sword; large-impact analysis and regression testing are re-
quired to fit these changes into existing CRFs and data-
sets. Compare this with a traditional trial where you
would take the lessons learnt and implement in your next
trial without any of the negative side effects.
Future work in developing data management when
adapting platform protocols could be to develop metrics
[12] from these and other relevant CTU-led trials to
more formally compare different approaches used for
CRFs and databases. Qualitative interviews with hospital
staff involved in adaptive designs and platform protocols
would be valuable, gathering their perspective on the
challenges of data management in the site setting.
Using Clinical Data Acquisition Standards Harmonisa-
tion for these trials may harmonise what needs to be col-
lected and help future-proof some questions from the
updates required with each new comparison. This has not
yet been explored in the platform protocols in our unit.
As described by our companion trial management paper,
early discussions with competent authorities is necessary
to prepare for successful submission of amendments. We
cannot comment on any findings in relation to data integ-
rity and safety in these types of trial designs, with these tri-
als not having been inspected to date. STAMPEDE was
recently audited by a collaborating pharmaceutical
Table 5 Summary of recommendations (Continued)
Process Risk to patient safety or data integrity? Recommendations
Competing,
concurrent tasks: data
queries and CRF
chases
Any data for comparisons that may not be queried
before any analyses during this time, risking data
quality during this time period.
Insufficient data cleaning before analyses is a risk to
data integrity for any trial. This may be greater in
shared control arm platform protocols because there
may be imbalance in reporting on the control arm if
this has been chased more frequently.
Plan for possibility of priority analyses occurring
close together,
without neglecting other comparisons.
Send queries for all comparisons where possible. If
volume is too
great, queries may have to be split by patient, site
or CRF.
Ensure both control and research comparisons are
sufficiently
chased and cleaned before analysis.
Check for imbalances in reporting between missing
expected forms
and triggered event forms in control arm and
research comparison
before any analysis.
Competing,
concurrent tasks:
opening new
comparisons while managing
existing comparisons
Data management in existing comparisons may be
neglected if staff spend time setting up new
comparison.
New comparisons may not adequately incorporate new data
requirements if staff are
working on existing comparisons.
Adequately resource for both ongoing data
management and the
work required for the addition of a new comparison
Consider competing trial priorities when planning to
activate a new comparison
CRF Case report form, eCRF Electronic case report form
aThe choice of in-house or third-party clinical data management system (CDMS) is likely made at a unit level, and there may not be scope for choosing a different
approach or for switching between third-party systems. Recommendations in table relating to how to set up any given CDMS should be considered to reduce size
and complexity where possible
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company, and the data management findings were not
related to the trial design.
Conclusions
Adaptive designs and platform protocols pose novel
challenges in data management, which have planning,
design and resource requirements different from those
needed for running more traditional trial designs. Some
challenges are shared with other large trials that run for
a long time, but the size and longevity may be harder to
predict when adaptive platform trials are originally set
up. Any trial that could potentially incorporate a new
comparison must future-proof CRFs and databases,
often without knowing the specific nature and number
of changes that may follow. This is in addition to the
principles set out for incorporating new comparisons
into an ongoing trial ([7];). For future trials of this na-
ture, our unit has committed to using a different CDMS,
with which we do not anticipate having the same issues
with performance when saving large amounts of data.
We also intend to implement comparison databases in a
modular fashion, where possible, to avoid the issue of
maintaining cumulative changes. Competing priorities
will exist as comparisons are added and closed while data
for ongoing multiple comparisons must be processed and
prepared for analysis, and this should be considered when
planning resource for the study. Often these trials amend
a single protocol, but the data management resource re-
quired is not likely to be equivalent to a single traditional
trial design.
The efficiencies of the adapting platform protocols are
increasingly well understood. However, these efficiencies
come with additional challenges, particularly in aspects
of data management. Our identification and possible so-
lutions for certain challenges should encourage other or-
ganisations to use adaptive platform protocols.
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